Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 symbols : Jnj save search
Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients
Published: 2023-11-14 (Crawled : 06:00) - globenewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.17%
H: 0.0%
C: 0.0%
adx7114 study phase 2
Addex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Q2 2024
Published: 2023-09-05 (Crawled : 05:00) - globenewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.58%
H: 0.0%
C: 0.0%
ADXN | News | $19.0 -9.35% -10.32% 20K
|
Health Technology
|
| O: 10.13%
H: 6.8%
C: 6.06%
adx7114 expected readout study phase 2
PAN-TB Collaboration Announces the Start of a Phase 2 Clinical Trial to Evaluate Two Novel Tuberculosis Treatment Regimens
Published: 2023-08-09 (Crawled : 17:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.16%
H: 0.0%
C: 0.0%
start treatment collaboration trial phase 2
ONL Therapeutics Closes First Tranche of $15 Million Series C Financing to Advance Lead Compound into Phase 2 Clinical Trial
Published: 2023-03-08 (Crawled : 14:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.07%
H: 0.14%
C: -0.66%
trial therapeutics phase 2
Bavarian Nordic’s COVID-19 Booster Vaccine Candidate Demonstrates Durable Antibody Response Six Months After Vaccination in Phase 2 Clinical Trial
Published: 2022-10-17 (Crawled : 07:00) - globenewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.63%
H: 0.0%
C: 0.0%
covid-19 candidate antibody vaccine six trial response phase 2
Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX® (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma
Published: 2022-08-27 (Crawled : 00:20) - prnewswire.com
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
GNMSF | $290.38 3.83% 220
|
Health Technology
| Email alert
Add to watchlist
darzalex study phase 2
PAN-TB Collaboration to Advance Investigational Tuberculosis Drug Regimens to Phase 2 Clinical Trials
Published: 2022-08-17 (Crawled : 13:20) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.4%
H: 0.0%
C: 0.0%
trials drug collaboration phase 2
Janssen Presents Initial Results from the Phase 2 RAGNAR Study of BALVERSA® (erdafitinib) in Patients with Advanced Solid Tumors with FGFR Alterations
Published: 2022-06-07 (Crawled : 15:00) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.18%
H: 0.0%
C: 0.0%
balversa results phase 2
Bavarian Nordic Reports Omicron Data from Phase 2 Trial of its COVID-19 Booster Vaccine Candidate
Published: 2022-05-05 (Crawled : 09:00) - globenewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.72%
H: 0.0%
C: 0.0%
covid-19 vaccine trial phase 2
Bavarian Nordic Reports Additional Positive Phase 2 Results for its COVID-19 Vaccine Candidate Ahead of Phase 3 Trial
Published: 2022-02-28 (Crawled : 07:00) - globenewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 1.79%
H: 0.0%
C: 0.0%
covid-19 phase 2 trial covid report positive phase 2 results results vaccine phase 3
The Majority of Adults with Moderately to Severely Active Crohn's Disease in a Phase 2 Study Achieved Clinical Remission and Corticosteroid-Free Remission Through 48 Weeks with TREMFYA® (guselkumab)
Published: 2022-02-18 (Crawled : 20:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.73%
H: 0.23%
C: -0.98%
tremfya phase 2 disease active
New Phase 2b Data Show the Majority of Adults with Moderately to Severely Active Ulcerative Colitis Achieved Clinical Response with TREMFYA® (guselkumab) at 12 Weeks
Published: 2022-02-18 (Crawled : 15:30) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.73%
H: 0.23%
C: -0.98%
tremfya phase 2 phase 2b response active pons ulcerative colitis
Bavarian Nordic Reports Positive Topline Phase 2 Results for its COVID-19 Vaccine Candidate
Published: 2021-12-05 (Crawled : 20:20) - globenewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
phase 2 covid positive phase 2 results results topline vaccine covid-19
Arrowhead Collaborator Presents Phase 2b Clinical Data from REEF-1 Study in Patients with Chronic Hepatitis B Infection
Published: 2021-11-15 (Crawled : 19:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -1.36%
H: 0.0%
C: 0.0%
ARWR | $22.33 -1.24% -1.25% 960K
|
Health Technology
|
| O: -3.29%
H: 0.86%
C: -10.19%
phase 2 hepatitis phase 2b injection infections chronic hepatitis b
Addex Strategic Partner Successfully Completes Phase 1 in Japan with ADX71149
Published: 2021-11-15 (Crawled : 09:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -1.36%
H: 0.0%
C: 0.0%
ADXN | News | $19.0 -9.35% -10.32% 20K
|
Health Technology
|
| O: 2.85%
H: 1.14%
C: 1.14%
phase 1 phase 2 xin phase 3
Janssen Announces Phase 2b Data Demonstrating its Investigational RSV Adult Vaccine Provided 80% Protection Against Lower Respiratory Infections in Older Adults
Published: 2021-10-02 (Crawled : 00:20) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
phase 2 respiratory vaccine phase 2b injection order infections
Arrowhead Earns $10 Million Phase 1 Milestone Payment
Published: 2021-09-28 (Crawled : 12:15) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.04%
H: 0.5%
C: -0.18%
ARWR | $22.33 -1.24% -1.25% 960K
|
Health Technology
|
| O: -0.99%
H: 0.0%
C: -6.56%
phase 1 phase 2 phase 3 milestone
Sanofi announces positive Phase 1/2 study interim results for its first mRNA-based vaccine candidate
Published: 2021-09-28 (Crawled : 07:00) - globenewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.04%
H: 0.5%
C: -0.18%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.15%
H: 0.06%
C: -0.6%
phase 1 positive results vaccine phase 2 phase 3
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
Published: 2021-09-22 (Crawled : 12:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.17%
H: 0.0%
C: -1.11%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.5%
H: 0.36%
C: -0.86%
ARCT 4 | $25.995 -1.23% -1.25% 630K
|
Health Technology
|
| O: 1.81%
H: 2.1%
C: -0.32%
phase 2 vaccine phase 3 approval sars-cov-2
Johnson & Johnson and Global Partners Announce Results from Phase 2b Imbokodo HIV Vaccine Clinical Trial in Young Women in Sub-Saharan Africa
Published: 2021-08-31 (Crawled : 12:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.1%
H: 0.58%
C: -0.21%
phase 2 women results vaccine phase 2b trial hiv africa
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
NYC 4 | $5.91 -4.83% 14.38% 770
|
Finance
GBR | $1.42 31.48% 11.27% 990K
|
Energy Minerals
DEO | News | $140.76 -0.02% 8.27% 560K
|
Consumer Non-Durables
KUKE | $2.88 2.49% 7.64% 360K
|
MGLD 4 | $1.23 8.85% 7.32% 14K
|
Manufacturing
GRFX | $0.2116 -1.58% 7.28% 40K
|
n/a
LYT | $4.22 4.72% 5.62% 1.4M
|
SYY | $76.73 1.44% 5.49% 2.5M
|
Distribution Services
TWI | $11.53 0.96% 4.94% 330K
|
Producer Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.